Biogen Valuation
Is BIIB * undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
5/6Valuation Score 5/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of BIIB * when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: BIIB * (MX$3700) is trading below our estimate of fair value (MX$6835.1)
Significantly Below Fair Value: BIIB * is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for BIIB *?
Other financial metrics that can be useful for relative valuation.
What is BIIB *'s n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | US$31.28b |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 3.8x |
Enterprise Value/EBITDA | 14.7x |
PEG Ratio | 1.5x |
Price to Earnings Ratio vs Peers
How does BIIB *'s PE Ratio compare to its peers?
Company | Forward PE | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 58.2x | ||
A068270 Celltrion | 73.1x | 40.3% | ₩39.2t |
BNTX BioNTech | 21.8x | -20.2% | US$21.4b |
HZNP Horizon Therapeutics | 60.8x | 16.4% | US$26.6b |
BMRN BioMarin Pharmaceutical | 77x | 29.5% | US$15.3b |
BIIB * Biogen | 27x | 17.8% | Mex$31.3b |
Price-To-Earnings vs Peers: BIIB * is good value based on its Price-To-Earnings Ratio (27x) compared to the peer average (57.3x).
Price to Earnings Ratio vs Industry
How does BIIB *'s PE Ratio compare vs other companies in the Global Biotechs Industry?
Price-To-Earnings vs Industry: BIIB * is good value based on its Price-To-Earnings Ratio (27x) compared to the Global Biotechs industry average (31.6x).
Price to Earnings Ratio vs Fair Ratio
What is BIIB *'s PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PE Ratio | 27x |
Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate BIIB *'s Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
---|---|---|---|---|---|---|---|
Current | Mex$3,700.00 | Mex$4,867.15 +31.5% | 13.6% | Mex$5,957.00 | Mex$3,404.00 | n/a | 30 |
Apr ’25 | Mex$3,523.00 | Mex$5,143.39 +46.0% | 12.7% | Mex$6,847.20 | Mex$3,937.14 | n/a | 30 |
Mar ’25 | Mex$3,762.46 | Mex$5,143.39 +36.7% | 12.7% | Mex$6,847.20 | Mex$3,937.14 | n/a | 30 |
Feb ’25 | n/a | Mex$5,390.64 0% | 11.1% | Mex$6,992.34 | Mex$4,219.51 | n/a | 30 |
Jan ’25 | Mex$4,416.53 | Mex$5,310.80 +20.2% | 10.2% | Mex$6,693.51 | Mex$4,060.28 | n/a | 31 |
Dec ’24 | Mex$4,017.00 | Mex$5,618.31 +39.9% | 11.1% | Mex$6,953.59 | Mex$4,218.04 | n/a | 29 |
Nov ’24 | Mex$4,315.00 | Mex$5,892.76 +36.6% | 9.2% | Mex$7,267.36 | Mex$4,832.79 | n/a | 29 |
Oct ’24 | n/a | Mex$5,754.38 0% | 10.5% | Mex$7,660.48 | Mex$4,726.30 | n/a | 29 |
Sep ’24 | n/a | Mex$5,473.99 0% | 10.2% | Mex$7,321.92 | Mex$4,517.42 | n/a | 28 |
Aug ’24 | Mex$4,514.00 | Mex$5,612.90 +24.3% | 9.7% | Mex$7,300.56 | Mex$4,621.45 | n/a | 28 |
Jul ’24 | Mex$4,815.00 | Mex$5,788.33 +20.2% | 8.5% | Mex$6,849.62 | Mex$4,526.26 | n/a | 27 |
Jun ’24 | Mex$5,300.00 | Mex$5,867.39 +10.7% | 8.4% | Mex$6,986.25 | Mex$4,616.54 | n/a | 27 |
May ’24 | Mex$5,010.00 | Mex$5,907.14 +17.9% | 8.8% | Mex$7,135.58 | Mex$4,715.22 | Mex$3,700.00 | 27 |
Apr ’24 | Mex$4,989.94 | Mex$6,042.94 +21.1% | 9.7% | Mex$7,270.27 | Mex$4,665.71 | Mex$3,523.00 | 26 |
Mar ’24 | Mex$4,961.50 | Mex$5,895.60 +18.8% | 9.6% | Mex$7,099.78 | Mex$4,556.30 | Mex$3,762.46 | 26 |
Feb ’24 | n/a | Mex$6,075.45 0% | 10.1% | Mex$7,545.22 | Mex$4,673.53 | n/a | 26 |
Jan ’24 | n/a | Mex$6,342.02 0% | 8.9% | Mex$7,325.04 | Mex$4,889.96 | Mex$4,416.53 | 26 |
Dec ’23 | Mex$5,727.69 | Mex$6,118.04 +6.8% | 9.3% | Mex$7,087.61 | Mex$4,731.46 | Mex$4,017.00 | 26 |
Nov ’23 | n/a | Mex$6,012.29 0% | 12.0% | Mex$7,296.36 | Mex$4,298.94 | Mex$4,315.00 | 26 |
Oct ’23 | Mex$5,400.00 | Mex$5,411.68 +0.2% | 17.6% | Mex$7,249.86 | Mex$3,826.32 | n/a | 26 |
Sep ’23 | n/a | Mex$4,739.69 0% | 14.2% | Mex$6,065.35 | Mex$3,639.21 | n/a | 26 |
Aug ’23 | n/a | Mex$4,926.89 0% | 14.2% | Mex$6,303.68 | Mex$3,782.21 | Mex$4,514.00 | 26 |
Jul ’23 | Mex$4,210.00 | Mex$4,863.32 +15.5% | 16.5% | Mex$6,870.98 | Mex$3,705.92 | Mex$4,815.00 | 27 |
Jun ’23 | Mex$3,902.08 | Mex$4,883.29 +25.1% | 17.8% | Mex$6,951.81 | Mex$3,674.53 | Mex$5,300.00 | 28 |
May ’23 | n/a | Mex$5,068.11 0% | 17.1% | Mex$7,151.45 | Mex$3,841.35 | Mex$5,010.00 | 28 |
Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.